
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is expected to continue delivering steady growth in its clinical services business, particularly through its faster-growing NGS segment, with potential upside from new test launches such as MRD and liquid profiling. Furthermore, the company has strong potential for margin expansion and significant cash flow improvement. With its position as a key player in the community channel for cancer care and a low valuation of <2x EV/2026 revenue, NeoGenomics presents an attractive investment opportunity. The company is also continuously expanding its test menu with innovative assays, which could lead to sustained revenue growth and a higher stock valuation.
Bears say
NeoGenomics is highly exposed to market share loss as private sophisticated lab competitors are gaining share through improved leverage of patient data and complex NGS reports that are replacing more of its clinical testing volume than anticipated. Furthermore, risks to the Medical and Life Science Tools sector may also negatively impact NEO, including reduced research and development budgets and government funding, decreased purchasing from healthcare/hospital customers, increased regulatory hurdles, and macroeconomic challenges. NEO also faces risks specific to its company, such as potential setbacks in RaDaR reimbursement or patent litigation, greater reinvestment leading to weaker EBITDA margins, negative changes to reimbursement, and the potential for losing market share to more focused competitors.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares